MS and Demyelinating Disorders

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]

The panel shares final advice for the multiple sclerosis community.

Craig Mainor shares advice for people living with multiple sclerosis and their families.

The senior academic at the University of Sydney discussed the reasons for using BC-LCLA and the modified MS Functional Composite in the phase 2 VISIONARY-MS trial. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Teri Schreiner, MD, associate professor at the University of Colorado, talked about the impact of B-cell-depleting therapy in pediatric patients with MS infected with COVID-19.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending May 13, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 12, 2023.

The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]

The strongest associations observed in the study were between microglial activation at the rim of chronic T1 hyperintense lesion and in the perilesional normal appearing white matter and serum neurofilament light.

Jeffrey Bennett, MD, PhD, professor of neurology and ophthalmology at the University of Colorado Denver talked about inebilizumab for patients with NMOSD from the N-MOmentum trial.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, consider reasons to use generic disease-modifying therapies (DMTs) as a first-line therapy in the treatment of relapsing remitting multiple sclerosis (RRMS).

Experts in neurology highlight factors that lead them to choose certain therapies to treat relapsing remitting multiple sclerosis (RRMS), such as high efficacy in clinical trials.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

The director and chief research scientist at Tisch MS Research Center of New York talked about a phase 2 data study on stem cell treatment for multiple sclerosis that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

The panel discusses access challenges faced by patients with multiple sclerosis.

The panel discusses the role of shared decision-making to improve treatment outcomes for patients living with multiple sclerosis.

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

In a subgroup of individuals with secondary progressive MS, 50% of patients on mesenchymal stem cell-neural progenitor therapy improved muscle strength compared with 33% of those on placebo.

Neurology News Network for the week ending May 6, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 5, 2023.

Teriflunomide, an FDA-approved therapy for relapsing forms of multiple sclerosis, resulted in an 62% risk reduction relative to placebo in preventing a first clinical event in patients with RIS.

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Gabriel Pardo, MD, FAAN, describes the process that generic RRMS medications have to go through to be approved by the FDA, highlighting the abbreviated new drug application [ANDA] process.

Expert neurologists review availability of generic disease-modifying therapies [DMTs] and the effectiveness of reduced cost to the patient with RRMS

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.